Uniqure N.V.. (2/6/17). "Press Release: Uniqure Announces Presentations at Upcoming February Conferences". Lexington, MA & Amsterdam.

	Region	New York, NY
	Country	United States (USA)
	Organisation	Uniqure N.V. (Nasdaq: QURE)
	Group	Uniqure (Group)
	Organisation 2	Leerink Partners LLC
	Today	SVB Leerink LLC
	Product	Leerink Partners Annual Global Healthcare Conference 2017 New York
	Product 2	AMT-060 (AAV5 hFIX) (Uniqure)
	Index term	Uniqure–Leerink: investor conference, 201702 supply service Uniqure presents at Leerink Partners Global Healthcare Conference in NYC
	Person	Kapusta, Matthew (Matt) (Uniqure 201612– CEO before interim CEO before CFO before AngioDynamics + Smith & Nephew)
	Person 2	Cantor, Maria E. (Uniqure 201606– SVP IR + Communications before Ariad Pharmaceuticals + Genzyme)

uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced presentations at the following conferences taking place in February:

Leerink Partners 6th Annual Global Healthcare Conference, at the Lotte New York Palace Hotel in New York City

> Matthew Kapusta, chief executive officer, will participate in a Fireside Chat on Wednesday, February 15th at 3.00 p.m. EST. The live webcast can be accessed by the link displayed in the Investor section of the uniQure website at: http://uniqure.com/investors-newsroom/overview.php. The webcast replay will be available for at least 72 hours following the live event.

61st Annual Meeting of Society of Thrombosis and Hemostatis Research at the Congress Center in Basel, Switzerland

> Professor Wolfgang Miesbach, M.D. professor of hematology at the University of Frankfurt, Germany and an investigator in the ongoing Phase 1-2 clinical trial of AMT-060 (AAV5 hFIX) gene transfer in adult patients with severe hemophilia B, will present previously disclosed interim results from the dose escalating study on Thursday, February 16th at 15.00 CET/ 09.00 a.m. EST.

About uniQure

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington's disease and cardiovascular diseases. www.uniQure.com

uniQure Contacts:

Maria E. Cantor
Direct: 339-970-7536
Mobile: 617-680-9452
m.cantor@uniQure.com

Tom Malone
Direct: 339-970-7558
Mobile: 339-223-8541
t.malone@uniQure.com

Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79
e.mulder@uniQure.com

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: uniQure N.V. via Globenewswire

Record changed: 2023-06-05